Overview of the Class
Glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin therapies form a family of medicines and investigational agents that act on hormones involved in glucose regulation, appetite, and energy balance. The class includes selective GLP-1 receptor agonists as well as newer dual and triple agonists that also engage receptors for glucose-dependent insulinotropic polypeptide (GIP) and, in some cases, glucagon or amylin.
At a high level, these agents are used and studied in the context of type 2 diabetes, chronic weight management, and broader metabolic health, with specific labeled indications varying by molecule and jurisdiction.
Mechanism of Action (Class Themes)
Although individual molecules differ, many GLP-1 and incretin-based therapies share recurring mechanistic themes (Drucker, Cell Metabolism 2018):
- Enhancing glucose-dependent insulin secretion from pancreatic beta cells
- Modulating glucagon secretion in a way that supports glycemic control
- Slowing gastric emptying and affecting postprandial glucose
- Acting on appetite-regulating centers in the brain to reduce hunger and energy intake
Dual and triple agonists extend these ideas by engaging additional receptors, which may influence energy expenditure, lipid handling, or satiety signaling. Exactly how these mechanisms combine in humans is an active area of research.
Safety and Side Effects (Class Themes)
Across the class, commonly reported side effects in studies have included gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), decreased appetite, and abdominal discomfort. These effects are often dose-related and may be mitigated by gradual dose escalation.
More serious but less frequent risks under active study include gallbladder-related issues, pancreatitis, and class-wide questions about long-term safety in specific populations. Risk–benefit decisions, contraindications, and monitoring strategies are molecule- and patient-specific and belong with prescribing clinicians.
Research and Evidence Themes
Research across this class includes large randomized trials in type 2 diabetes and obesity, cardiovascular outcome studies, and trials with liver and kidney endpoints. As one benchmark of scale, the STEP 1 trial (n=1,961) reported a mean body-weight reduction of 14.9% with once-weekly semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks (NEJM 2021).
Entries in this Class (9)
Frequently Asked Questions
How do selective GLP-1 agonists differ from dual and triple agonists?
Selective agents act only at the GLP-1 receptor, while dual agonists add GIP receptor activity and triple agonists add glucagon receptor activity on top of that. The additional receptors are thought to influence energy expenditure and lipid handling beyond appetite and glycemic effects, though how the mechanisms combine in humans is still being worked out molecule by molecule.
What outcomes are typically measured in trials of this class?
Diabetes trials center on glycemic control (typically HbA1c) alongside body weight, while weight-management trials use percentage body-weight change as the primary endpoint. Larger outcome studies track cardiovascular events, and safety monitoring watches gastrointestinal tolerability, gallbladder issues, and pancreatitis.
Why do side effects differ so much between people?
Gastrointestinal effects are dose-related and vary with how quickly the dose is escalated, which is why labeled regimens titrate gradually. Individual differences in gastric emptying, diet, and concurrent conditions also play a role — one reason risk–benefit decisions for any specific molecule belong with a prescribing clinician.
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.